Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting.
anti‐obesity agents
obesity
paediatric obesity
phentermine
Journal
Pediatric obesity
ISSN: 2047-6310
Titre abrégé: Pediatr Obes
Pays: England
ID NLM: 101572033
Informations de publication
Date de publication:
17 Jun 2024
17 Jun 2024
Historique:
revised:
12
05
2024
received:
09
06
2023
accepted:
17
05
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
Anti-obesity medications (AOMs) are promising lifestyle modification (LSM) adjuncts for obesity treatment, and phentermine is commonly prescribed in paediatric weight management clinics. Determining 'real-world' AOM effectiveness and characteristics predicting response is important. We sought to describe phentermine plus LSM effectiveness and identify baseline characteristics predicting response. This was a retrospective cohort study among youth seen in a US academic-based weight management clinic from 2012 to 2020. Baseline characteristics (e.g., body mass index (BMI), liver transaminases, eating-related behaviours) and outcomes (%BMI of 95th percentile (%BMIp95), BMI, %BMI change, weight) were determined through electronic health records and intake surveys. Among 91 youth prescribed phentermine plus LSM over 8 years (mean %BMIp95 150%), %BMIp95 was statistically significantly reduced at 1.5, 3, 6 and 12 months (peak reduction 10.9 percentage points at 6 months; p < 0.001). Considering multiple comparisons, the presence of baseline elevated alanine aminotransferase was associated with statistically significant smaller 1.5-month %BMIp95 reductions (p = 0.001) and higher food responsiveness with smaller 3- (p = 0.001) and 6-month (p < 0.001) reductions. Phentermine plus LSM reduced %BMIp95 among youth in a weight management clinic, and baseline characteristics may help determine those more or less likely to respond. Prospective studies are needed to further characterize effectiveness and confirm response predictors.
Sections du résumé
BACKGROUND
BACKGROUND
Anti-obesity medications (AOMs) are promising lifestyle modification (LSM) adjuncts for obesity treatment, and phentermine is commonly prescribed in paediatric weight management clinics. Determining 'real-world' AOM effectiveness and characteristics predicting response is important.
OBJECTIVES
OBJECTIVE
We sought to describe phentermine plus LSM effectiveness and identify baseline characteristics predicting response.
METHODS
METHODS
This was a retrospective cohort study among youth seen in a US academic-based weight management clinic from 2012 to 2020. Baseline characteristics (e.g., body mass index (BMI), liver transaminases, eating-related behaviours) and outcomes (%BMI of 95th percentile (%BMIp95), BMI, %BMI change, weight) were determined through electronic health records and intake surveys.
RESULTS
RESULTS
Among 91 youth prescribed phentermine plus LSM over 8 years (mean %BMIp95 150%), %BMIp95 was statistically significantly reduced at 1.5, 3, 6 and 12 months (peak reduction 10.9 percentage points at 6 months; p < 0.001). Considering multiple comparisons, the presence of baseline elevated alanine aminotransferase was associated with statistically significant smaller 1.5-month %BMIp95 reductions (p = 0.001) and higher food responsiveness with smaller 3- (p = 0.001) and 6-month (p < 0.001) reductions.
CONCLUSIONS
CONCLUSIONS
Phentermine plus LSM reduced %BMIp95 among youth in a weight management clinic, and baseline characteristics may help determine those more or less likely to respond. Prospective studies are needed to further characterize effectiveness and confirm response predictors.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13143Subventions
Organisme : NCATS NIH HHS
ID : UL1TR002494
Pays : United States
Organisme : Division of Diabetes, Endocrinology, and Metabolic Diseases
ID : K23DK125668
Informations de copyright
© 2024 The Author(s). Pediatric Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Références
Stierman B, Afful J, Carroll MD, et al. National health and nutrition examination survey 2017 – march 2020 prepandemic data files – development of files and prevalence estimates for selected health outcomes. Nat Health Stat Rep. 2021;158:1‐21.
Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999–2016. Pediatrics. 2018;141(3):e20173459.
Danielsson P, Kowalski J, Ekblom O, Marcus C. Response of severely obese children and adolescents to behavioral treatment. Arch Pediatr Adolesc Med. 2012;166(12):1103‐1108.
Borzutzky C, King E, Fox CK, et al. Trends in prescribing anti‐obesity pharmacotherapy for paediatric weight management: data from the POWER work group. Pediatr Obes. 2021;16(1):e12701.
Bomberg EM, Ryder JR, Brundage RC, et al. Precision medicine in adult and pediatric obesity: a clinical perspective. Ther Adv Endocrinol Metab. 2019;10:1‐25.
Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10‐year period. Arch Intern Med. 2001;161:1581‐1586.
Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med. 1999;341(6):427‐434.
Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968‐976.
Aune D, Sen A, Norat T, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose‐response meta‐analysis of prospective studies. Circulation. 2016;133:639‐649.
Kelly AS, Marcus MD, Yanovski JA, Yanovski SZ, Osganian SK. Toward precision medicine approaches to treat severe obesity in adolescents: report of an NIH workshop. Int J Obes (Lond). 2018;42:1834‐1844.
Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, Fox CK. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes (Lond). 2017;41(1):90‐93.
Buffenstein I, Kaneakua B, Taylor E, et al. Demographic recruitment bias of adults in United States randomized clinical trials by disease categories between 2008 and 2019: a systematic review and meta‐analysis. Sci Rep. 2023;13:42.
Thomas CE, Mauer EA, Shukla AP, Rathi S, Aronne LJ. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring). 2016;24:1955‐1961.
Bomberg EM, Palzer EF, Rudser KD, et al. Anti‐obesity medication prescriptions by race/ethnicity and use of an interpreter in a pediatric weight management clinic. Ther Adv Endocrinol Metab. 2022;13:204201882210900. doi:10.1177/20420188221090009
Kelly AS, Bensignor MO, Hsia DS, et al. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1(6):1‐18. doi:10.1056/evidoa2200014
Weghuber D, Barrett T, Barrientos‐Perez M, et al. Once‐weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245‐2257.
Kelly AS, Auerbach P, Barrientos‐Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117‐2128.
Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143‐157.
Davis C, Fattore L, Kaplan AS, Carter JC, Levitan RD, Kennedy JL. The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. Int J Neuropsychopharmacol. 2012;15:181‐187.
Moens E, Braet C, Van Winckel M. An 8‐year follow‐up of treated obese children: children's, process and parental predictors of successful outcome. Behav Res Ther. 2010;48:626‐633.
LiverTox: Clinical and Research Information on Drug‐Induced Liver Injury [Internet]: Phentermine. National Institute of Diabetes and Digestive and Kidney Diseases. 2020 Accessed 2023. https://www.ncbi.nlm.nih.gov/books/NBK547916/
Stanke‐Labesque F, Gautier‐Veyret E, Chhun S, Guilhamou R. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215:107627.
Rheinwalt KP, Drebber U, Schierwagen R, et al. Baseline presence of NAFLD predicts weight loss after gastric bypass surgery for morbid obesity. J Clin Med. 2020;9(11):3430.
Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BJ. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24(1):18‐33.
Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta‐analysis. Int J Obes (Lond). 2010;34:407‐419.
Heo Y, Duggan ST. Lisdexamfetamine: a review in binge eating disorder. CNS Drugs. 2017;31:1015‐1022.
Dornoff SE, Miller AL, Kaciroti N, Lumeng JC. Validation of the Children's eating behavior questionnaire in a low‐income pre‐school‐aged sample in the United States. Appetite. 2015;95:415‐420.
Kelly AS, Daniels SR. Rethinking the use of body mass index z‐score in children and adolescents with severe obesity: time to kick it to the curb? J Pediatr. 2017;188:7‐8.
Wardle J, Guthrie CA, Sanderson S. Rapoport L development of the Children's eating behaviour questionnaire. J Child Psychology Psych. 2001;42:963‐970.
Sleddens EFC, Kremers SPJ, Thijs C. The Children's eating behavior questionnaire: factorial validity and association with body mass index in Dutch children aged 6‐7. Int J Behav Nutr Physical Act. 2008;5(49):1‐9.
Snyder RA, Chang GJ. Insurance status as a surrogate for social determinants of health in cancer clinical trials. JAMA Netw Open. 2020;3(4):e203890.
Holm S. A simple sequentially rejective multiple test procedure. Scand Stat Theory Appl. 1979;6(2):65‐70.
Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health. 1996;86(5):726‐728.
Antel J, Hebebrand J. Weight‐reducing side effects of the antiepileptic agents topiramate and zonisamide. In: Joost H, ed. Appetite Control. Springer; 2012:433‐466.
Bray GA, Kim KK, Wilding JPH, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the world obesity federation. Obes Rev. 2017;18(7):715‐723.
Kumar S, King EC, Christison AL, et al. Health outcomes of youth in clinical pediatric weight management programs in POWER. J Pediatr. 2019;208:57‐65.
Ali Ibrahim AI, Mendoza B, Stanford FC, Malhotra S. Real‐world experience of the efficacy and safety of phentermine use in adolescents: a case series. Child Obes. 2022;19:535‐540. doi:10.1089/chi.2022.0147
United States Preventive Task Force, Grossman DC, Bibbins‐Domingo K, et al. Screening for obesity in children and adolescents: US preventive services task Formce recommendation statement. Jama. 2017;317(23):2417‐2426.
Gudzune KA, Johnson VR, Bramante CT, Stanford FC. Geographic availability of physicians certified by the American Board of Obesity Medicine relative to obesity prevalence. Obesity (Silver Spring). 2019;27(12):1958‐1966.
Pan CS, Stanley TL. Effect of weight loss medications on hepatic steatosis and steatohepatitis: a systematic review. Front Endocrinol (Lausanne). 2020;11:70. doi:10.3389/fendo.2020.00070
Carnell S, Wardle J. Measuring behavioral susceptibility to obesity: validation of the child eating behavior questionnaire. Appetite. 2007;48(1):104‐113.
Gianfrancesco MA, Tamang S, Yazdany J, Schmajuk G. Potential biases in machine learning algorithms using electronic health record data. JAMA Int Med. 2018;178:1544‐1547.
Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.
Appelhans BM, French SA, Martin MA, Lui K, Janssen I. Attenuated efficacy of pediatric obesity treatment during the COVID‐19 pandemic. Obesity (Silver Spring). 2022;30(1):45‐49.
Saxon DR, Iwamoto SJ, Mettenbrink CJ, et al. Anti‐obesity medication use in 2.2 million adults across 8 large healthcare organizations: 2009–2015. Obesity (Silver Spring). 2019;27(12):1975‐1981.
Del Re AC, Frayne SM, Harris AHS. Antiobesity medication use across the veterans health administration: patient‐level predictors of receipt. Obesity (Silver Spring). 2014;22:1968‐1972.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statist Med. 2015;34:3661‐3679.
Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity‐assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709‐757.